Centre for Cancer Biomarkers

Norwegian Centre of Excellence
The Research Council of Norway

# 3rd International p53 Isoforms Conference

## Bergen 18-21 June 2017

# Scientific program

## Day 1, Sunday June 18, 2017 Registration from 2pm

| | |
|---|---|
| 16.00-16.15 | Prof Lars A. Akslen: *Opening and introduction* |
| | **Session 1: p53 isoforms as biomarkers** |
| 16.15-16.40 | Prof Bjorn Tore Gjertsen: *p53 beta and gamma isoforms in normal leukocytes and acute leukemia* |
| 16.40-17.05 | Dr Stian Knappskog: *p53 isoforms as biomarkers in metastatic colon cancer* |
| 17.05-17.30 | Prof Kanaga Sabapathy: *Functional analysis of p47 (Δ40p53), the amino-terminal truncated isoform of p53* |
| 17.30-17.55 | Dr Kelly Avery-Kiejda*: Deciphering the complex role of Δ40p53 in breast cancer* |
| 17.55-18.40 | **Keynote:** Prof Antony Braithwaite: *Functions of the Δ133p53 isoform in immune regulation* |
| 19.00-21.00 | **Cocktails and poster session** |

## Day 2, Monday 19th June 2017

| | |
|---|---|
| | **Session 2: TP53 mutation and p53 isoforms as biomarkers** |
| 08.25-08.50 | Prof Moshe Oren: *A comprehensive library of p53 variants elucidates patterns of evolutionary conservation and mutations in cancer* |
| 08.50-09.05 | Dr Elisabeth Maritschnegg: *Examination of the presence and clinical significance of p53 prions in ovarian cancer* |
| 09.05-09.30 | Dr Oleg Laptenko: *Biological activities of mutant p53 proteins resulting from an open reading frame shifts that demonstrate significant structural similarity to TAp53 beta and gamma isoforms* |
| 09.30-09.45 | Dr Sunali Mehta: *A Study of TP53 RNA Splicing Illustrates Pitfalls of RNA-seq methodology* |
| 09.45-10.00 | Dr Brianna Morten: *The difficulties of measuring the p53 isoforms at the gene and protein levels: A tale of caution* |
| 10.00-10.25 | Prof Michal Sharon: *Post-translational regulation of p53 function through 20S proteasome-mediated cleavage* |

| | |
|---|---|
| 10.25-10.45 | **Coffee break** |
| 10.45-11.30 | **Keynote:** Prof Judith Campisi: *Control of cellular senescence aging and cancer by p53* |
| 11.30-11.55 | Prof David Malkin: *p53 'Epi' events in Li-Fraumeni Syndrome* |
| 11.55-12.10 | Dr Hind Hafsi: *p53 isoforms as mutation targets in cancer: lessons from public databases* |
| 12.10-12.25 | Stephanie Schubert: *TP53 beta variants in colorectal cancer predisposition* |
| 12.25-12.50 | Dr Pan Pantziarka: *Drug Repurposing And Reducing Cancer Incidence in Li Fraumeni Syndrome* |
| 12.50-14.20 | **Lunch break and poster session** |

## Session 3 : p53-based therapy

| | |
|---|---|
| 14.20-14.45 | Prof Klas Wiman: *Novel cancer therapy by reactivation of missense and nonsense mutant p53* |
| 14.45-15.00 | Dr Naoise Synnott: *Mutant p53 as A Therapeutic Target for the Treatment of Triple-Negative Breast Cancer: Preclinical Investigation with the Anti-p53 Drug, APR246* |
| 15.00-15.25 | Prof Chandra Verma: *p53 isoforms in drug discovery: modelling novel druggable interactions* |
| 15.25-15.40 | Dr Joanna Zawacka-Pankau: *Pharmacological re-activation of p53 protein family members affects proliferation and migration of cancer cells with TP53 gene mutations* |
| 15.40-16.05 | Prof Varda Rotter: *Re-activating mutant p53 into a wild type p53 by p53-small peptides* |
| 16.05-16.25 | **Coffee break** |

## Session 4: How to control cell reprogramming and tissue regeneration? Lessons from the interaction infectious pathogens/p53 isoforms

| | |
|---|---|
| 16.25-17.10 | **Keynote:** Prof Thomas Meyer: *The enigmatic link between infection and the early onset of TP53 mutations in cancer* |
| 17.10-17.35 | Dr Roy Chowdhury: *The Unfragmented Relationship between Chlamydia and Mitochondria: A p53 Story* |
| 17.35-18.00 | Dr Olivier Terrier: *Hijacking of p53 functions in human infections: each virus has its own way* |
| 18.00-18.15 | Dr Julia Dubois: *Interplay between influenza viruses and the alternative splicing of TP53* |
| 18.15-18.40 | Sebastien Joruiz: *Which p53 isoforms is the most important? Lesson from HPV* |

# Day 3, Tuesday 20th June 2017

## Session 5: p53 isoform in cancer, ageing, reprogramming

| | |
|---|---|
| 08.30-09.15 | **Keynote:** Prof Curtis C. Harris: *p53 Isoforms, Aging and Cancer* |
| 09.15-09.40 | Prof Pierre Roux: *The multiple roles of Δ133p53β in cancer progression* |
| 09.40-09.55 | Dr Marina Kazantseva: *Elevated Δ133p53β in prostate tumours correlates with an immune suppressive signature and poorer outcome* |
| 09.55-10.40 | **Keynote:** Prof Mina Bissel: *The crucial roles of Laminins and p53 isoforms in tissue specificity and gene expression: a perfect tango of Dynamic Reciprocity in 3-D* |
| 10.40-11.00 | **Coffee break** |

## Session 6 – effects of extra cellular matrix on p53

| | |
|---|---|
| 11.00-11.25 | Dr Sun-Young Lee: *Interplay between p53 isoforms and extracellular signaling in maintaining tissue-specific form and function* |
| 11.25-11.50 | Prof Giannino Del Sal: *Cell stiffness induced mechano-signaling in cancer: mutant p53 is at the crossroads* |
| 11.50-12.05 | Dr Angelo Peschiaroli: *ΔNp63-mediated regulation of hyaluronic acid metabolism and signaling supports HNSCC tumorigenesis* |
| 12.05-12.30 | Dr Patricia Muller: *Mutant p53alpha isoform drives cancer cell engulfment activity, leading to cell-in-cell structures that associate with tumourigenesis and recurrence* |
| 12.30-14.00 | **Lunch break and poster session** |

## Session 7 – Degeneration and regeneration

| | |
|---|---|
| 14.00-14.45 | **Keynote:** Prof David Kaplan: *The p53 family in neurodegeneration and stem cell aging* |
| 14.45-15.00 | Dr Izumi Horikawa: *Δ133p53 represses p53-inducible senescence genes and enhances the generation of human induced pluripotent stem cells* |
| 15.00-15.15 | Dr Tania Slatter: *Improving the prognosis from glioblastoma by targeting subtypes characterised by increased Δ133p53β or mutant p53* |
| 15.15-15.40 | Prof Simone Di Giovanni: *Regenerative transcriptional signalling networks for axonal regeneration and functional recovery: from p53 to epigenetic reprogramming* |
| 15.40-16.00 | **Coffee break** |

| | |
|---|---|
| 16.00-16.15 | Dr Martin Fischer: *Integrative analysis reveals common and distinct targets of the p53 gene regulatory network in the mouse and human genome* |
| 16.15-16.40 | Prof Joaquin Maximilano Espinosa: *Identification of a core p53 transcriptional program with highly distributed tumor suppressive activity* |
| 16.40-17.05 | Dr Simon McDade: *ΔNp63γ is both necessary and sufficient to activate SRC/AKT signalling axis and SNAI2-mediated EMT and invasion* |
| 17.05-17.30 | Prof David Meek: *The potential for regulating different forms of p53 by post-translation modification* |
| 17.30-18.15 | **Keynote:** Dr Jean-Christophe Bourdon: *p53: a system of protein isoforms. How does it work?* |
| 18.15 | **Drinks and mingling** |

## Day 4, Wednesday 21st June 2017

### Session 8: p53 family isoform in cancer and evolution

| | |
|---|---|
| 08.30-09.15 | **Keynote**: Prof Sir David Lane: *The discovery of new p53 isoforms in Zebrafish* |
| 09.15-09.40 | Prof Gerry Melino: *The p53 family in cancer biology (p63 and microenvironment)* |
| 09.40-09.55 | Dr Yari Ciribilli: *p53 isoforms are differentially expressed in human melanomas* |
| 09.55-10.15 | **Coffee break** |
| 10.15-10.30 | Dr Neda Slade: *The expression of p53/p73 isoforms, NME and GLI in melanoma cell lines* |
| 10.30-10.45 | Dr Yann Audic: *Control of DeltaNp63alpha/gamma ratio by the RNA binding protein Ptbp1 in Xenopus laevis development* |
| 10.45-11.10 | Prof Bertrand Mollereau: *p53 integrates the antagonism between autophagy and apoptosis in response to stress* |
| 11.10 | Dr Jean-Christophe Bourdon: *Conclusion* |